Phase II trial of EMA 401 for the treatment of pain and hypersensitivity in patients with peripheral nerve injuries.

Trial Profile

Phase II trial of EMA 401 for the treatment of pain and hypersensitivity in patients with peripheral nerve injuries.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs EMA 401 (Primary)
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Sponsors Spinifex Pharmaceuticals
  • Most Recent Events

    • 27 Feb 2014 Status changed from not yet recruiting to discontinued, as reported by Australian New Zealand Clinical Trials Registry.
    • 24 Jul 2012 Planned initiation date changed from 1 Mar 2012 to 1 Feb 2013 as reported by Australian New Zealand Clinical Trials Registry.
    • 06 Dec 2011 Planned patient number is 40 according Australian New Zealand Clinical Trials Registry record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top